UY36224A - Compuestos tricíclicos de imidazo-pirimidinona - Google Patents
Compuestos tricíclicos de imidazo-pirimidinonaInfo
- Publication number
- UY36224A UY36224A UY0001036224A UY36224A UY36224A UY 36224 A UY36224 A UY 36224A UY 0001036224 A UY0001036224 A UY 0001036224A UY 36224 A UY36224 A UY 36224A UY 36224 A UY36224 A UY 36224A
- Authority
- UY
- Uruguay
- Prior art keywords
- pirimidinona
- imidazo
- tricyclic compounds
- pla2
- activity
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102000016752 1-Alkyl-2-acetylglycerophosphocholine Esterase Human genes 0.000 abstract 2
- 108010024976 Asparaginase Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014000695 | 2014-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY36224A true UY36224A (es) | 2016-01-29 |
Family
ID=55162512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001036224A UY36224A (es) | 2014-07-22 | 2015-07-21 | Compuestos tricíclicos de imidazo-pirimidinona |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9783546B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3172211B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6625603B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20170029516A (cg-RX-API-DMAC7.html) |
| CN (2) | CN106536525B (cg-RX-API-DMAC7.html) |
| AR (1) | AR101261A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015292049B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016030939B1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2970537C (cg-RX-API-DMAC7.html) |
| ES (2) | ES2747636T3 (cg-RX-API-DMAC7.html) |
| RU (2) | RU2690190C2 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201617348A (cg-RX-API-DMAC7.html) |
| UY (1) | UY36224A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2016011931A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106536525B (zh) * | 2014-07-22 | 2019-05-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 化合物 |
| WO2017151939A1 (en) | 2016-03-02 | 2017-09-08 | The Brigham And Women's Hospital, Inc. | Use of pla2g5-deficient suppressive macrophages in suppression of inflammation |
| US11583596B2 (en) * | 2017-09-26 | 2023-02-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Radiolabeled Darapladib and analogs thereof and their use as imaging compounds |
| CN109988126B (zh) * | 2017-12-29 | 2023-05-16 | 南京富润凯德生物医药有限公司 | 一种3-氨基-氧杂环丁烷衍生物及其制备方法和应用 |
| CN109134523A (zh) * | 2018-09-30 | 2019-01-04 | 中昊(大连)化工研究设计院有限公司 | 一种3，6-二氢-2h-吡喃-4-硼酸频哪醇酯的合成新工艺 |
| JP2022116370A (ja) * | 2019-06-13 | 2022-08-10 | アグロカネショウ株式会社 | 新規な１－ベンジルアミン誘導体及びこれを有効成分とする農園芸用薬剤 |
| CN112574221B (zh) * | 2019-09-30 | 2022-03-04 | 上海纽思克生物科技有限公司 | 四环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| IL292668A (en) * | 2019-11-09 | 2022-07-01 | Shanghai Simr Biotechnology Co Ltd | A tricyclic derivative of dihydroimidazopyrimidone, its preparation method, pharmaceutical preparation and its use |
| CN113666930B (zh) * | 2020-05-13 | 2022-10-25 | 上海纽思克生物科技有限公司 | 桥环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| KR102842485B1 (ko) * | 2020-05-13 | 2025-08-05 | 뉴스코 바이오테크 리미티드 | 가교 환상 피리미디논류 화합물, 그의 제조방법, 그의 조성물 및 사용 |
| CN113861220B (zh) * | 2020-06-30 | 2023-06-16 | 上海纽思克生物科技有限公司 | 三环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| CN113912622B (zh) * | 2020-07-10 | 2023-12-01 | 上海纽思克生物科技有限公司 | 三环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| CN114057740B (zh) * | 2021-12-15 | 2024-04-02 | 上海赛默罗生物科技有限公司 | 螺环嘧啶酮衍生物、其制备方法、药物组合物和用途 |
| KR20250055539A (ko) * | 2022-08-04 | 2025-04-24 | 4비 테크놀로지스 (베이징) 컴퍼니 리미티드 | Lp-pla2 억제제로서의 디하이드로이미다조-피리미디논 화합물 및 이의 용도 |
| WO2024220459A2 (en) * | 2023-04-18 | 2024-10-24 | Scineuro Therapeutics Inc. | Combination therapy with lp-pla2 inhibitor and a second agent |
| TWI896037B (zh) * | 2023-07-17 | 2025-09-01 | 大陸商上海樞境生物科技有限公司 | 雙環[5,6]咪唑嘧啶酮類衍生物、其製備方法和應用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0127143D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| WO2004014923A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| GB0320522D0 (en) | 2003-09-02 | 2003-10-01 | Glaxo Group Ltd | Formulation |
| WO2009147476A1 (en) | 2008-06-02 | 2009-12-10 | Matrix Laboratories Ltd. | Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation |
| EP2619203A4 (en) * | 2010-09-20 | 2014-04-16 | Glaxo Group Ltd | TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF |
| JP2013545792A (ja) * | 2010-12-17 | 2013-12-26 | グラクソ グループ リミテッド | 眼疾患の処置および防止方法 |
| ES2773480T3 (es) * | 2011-05-09 | 2020-07-13 | Eip Pharma Llc | Composiciones y métodos para tratar la enfermedad de Alzheimer |
| CA2843102A1 (en) * | 2011-07-27 | 2013-01-31 | Glaxo Group Limited | Bicyclic pyrimidone compounds |
| JP2014521611A (ja) | 2011-07-27 | 2014-08-28 | グラクソ グループ リミテッド | Ｌｐ−ＰＬＡ２阻害剤としての２，３−ジヒドロイミダゾ［１，２−ｃ］ピリミジン−５（１Ｈ）−オン化合物の使用 |
| CN103827118B (zh) * | 2011-07-27 | 2016-03-09 | 葛兰素集团有限公司 | 双环嘧啶酮化合物 |
| EP2768517A4 (en) | 2011-10-17 | 2015-03-11 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| JP6065786B2 (ja) | 2012-09-14 | 2017-01-25 | 信越化学工業株式会社 | 化学増幅レジスト材料及びパターン形成方法 |
| US20150344485A1 (en) * | 2013-01-25 | 2015-12-03 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic pyrimidone compounds as inhibitors of lp-pla2 |
| AU2014209949B2 (en) * | 2013-01-25 | 2016-09-08 | Glaxosmithkline Intellectual Property Development Limited | 2,3-dihydroimidazol(1,2-c)pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (Lp-PLA2) inhibitors |
| CN103927116A (zh) * | 2014-03-18 | 2014-07-16 | 兴唐通信科技有限公司 | 基于触屏设备的手势输入汉字的键盘和方法 |
| CN106536525B (zh) * | 2014-07-22 | 2019-05-03 | 葛兰素史密斯克莱知识产权发展有限公司 | 化合物 |
-
2015
- 2015-07-21 CN CN201580040421.XA patent/CN106536525B/zh active Active
- 2015-07-21 CN CN201580039345.0A patent/CN106536521B/zh active Active
- 2015-07-21 UY UY0001036224A patent/UY36224A/es unknown
- 2015-07-21 AU AU2015292049A patent/AU2015292049B2/en not_active Ceased
- 2015-07-21 AR ARP150102300A patent/AR101261A1/es unknown
- 2015-07-21 JP JP2017503504A patent/JP6625603B2/ja active Active
- 2015-07-21 WO PCT/CN2015/084607 patent/WO2016011931A1/en not_active Ceased
- 2015-07-21 WO PCT/CN2015/084606 patent/WO2016011930A1/en not_active Ceased
- 2015-07-21 KR KR1020177001425A patent/KR20170029516A/ko not_active Withdrawn
- 2015-07-21 US US15/327,685 patent/US9783546B2/en active Active
- 2015-07-21 RU RU2017105353A patent/RU2690190C2/ru not_active IP Right Cessation
- 2015-07-21 RU RU2017105476A patent/RU2017105476A/ru not_active Application Discontinuation
- 2015-07-21 EP EP15825267.6A patent/EP3172211B1/en active Active
- 2015-07-21 EP EP15824385.7A patent/EP3172208B1/en active Active
- 2015-07-21 US US15/327,706 patent/US10125141B2/en active Active
- 2015-07-21 KR KR1020177001423A patent/KR20170034889A/ko not_active Withdrawn
- 2015-07-21 AU AU2015292048A patent/AU2015292048B2/en not_active Ceased
- 2015-07-21 BR BR112016030939-1A patent/BR112016030939B1/pt active IP Right Grant
- 2015-07-21 CA CA2970537A patent/CA2970537C/en active Active
- 2015-07-21 CA CA2955910A patent/CA2955910C/en active Active
- 2015-07-21 JP JP2017503553A patent/JP6625604B2/ja active Active
- 2015-07-21 ES ES15825267T patent/ES2747636T3/es active Active
- 2015-07-21 ES ES15824385T patent/ES2744339T3/es active Active
- 2015-07-21 TW TW104123494A patent/TW201617348A/zh unknown
-
2018
- 2018-09-27 US US16/143,788 patent/US10428078B2/en active Active
-
2019
- 2019-07-29 US US16/524,238 patent/US11999746B2/en active Active
-
2024
- 2024-04-25 US US18/646,178 patent/US20240300965A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
| GT201600147A (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2 | |
| SV2018005709A (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| CO2017011851A2 (es) | Compuestos novedosos | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| MX2020011104A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
| GT201600233A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| DOP2016000195A (es) | Compuestos | |
| MX369041B (es) | Proteinas quimericas tipo fosfatasa alcalina. | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
| CL2016000063A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| MX395231B (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. | |
| SV2017005412A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| MX2017007377A (es) | Compuestos organicos. | |
| CL2016000148A1 (es) | Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| MX2016012784A (es) | Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. | |
| DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t |